
|Videos|November 8, 2013
Comparing Treatment Options in Ovarian Cancer
Author(s)James T. Thigpen, MD
James T. Thigpen, MD, discusses the comparison of treatment options in ovarian cancer.
Advertisement
James T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the comparison of treatment options in ovarian cancer.
Clinical Pearls
- In ovarian cancer studies, researchers cannot control what therapies a patient will receive following progression on a study therapy
- These additional lines of therapy have an impact on survival, making it difficult to make an accurate comparison of therapies
- Using progression-free survival (PFS) as an endpoint may allow for a clean comparison
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















